Developmental Research Program (DRP) The DRP will continue to be carried out for the purpose of identifying and facilitating innovative new pilot projects in head and neck cancer (HNC) research. The specific goals of this Program are: 1) to provide seed funding opportunities for initial investigation of promising novel research in HNC; 2) to stimulate basic, clinical, and translational HNC research in areas of high priority to the SPORE; 3) to facilitate development of pilot projects into full project status in the SPORE or to be competitive for independent investigator-initiated proposals to other funding agencies; and 4) to increase the visibility of SPORE activities and increase participation among the institution?s clinicians and researchers. Our design for the DRP in this renewal application is similar to the process used during the first grant period, which proved successful. Drs. Jennifer R. Grandis, Robert L. Ferris, and Jonas T. Johnson, and all with ongoing experience in administering this Developmental Program, will continue to provide leadership for this program to foster translational head and neck cancer research. During the past grant period, the DRP funded 11 DRP projects in basic, translational, and clinical research. The DRP Directors track the progress of the successful applications and assign mentors to funded investigators to ensure that they obtain any needed services from the SPORE Cores and that they are effectively integrated into the SPORE program. Awardees present their research results to the SPORE investigators after one year of funding to be eligible for a second year of support. Progress toward translation as well as impact and innovation will determine whether DRP projects are found to merit promotion to full SPORE projects. In the past funding period, productive and innovative research funded by DRP awards to Drs. J. Bauman (and D. Johnson) and Y. Nikiforov (and L. Yip and U. Duvvuri) have been promoted to full projects, Projects 1 and 4 respectively, in this renewal application. Awardees are also assigned mentors and advised, as appropriate, in the preparation of grant applications for funding outside the SPORE mechanism and given access to SPORE Core resources to aid in this endeavor. DRP-supported research has led to 4 NIH awards (R01CA112219, R01EB016516, R21CA167373, & R21CA180211). There are also several grant applications submitted or planned based on DRP results from the previous grant period, including an R21 and two additional R01 applications. The DRP will continue to utilize institutional web-based resources to solicit proposals from notify the research community at the Univ. of Pittsburgh. A standing DRP Committee, together with ad hoc reviewers with specific expertise as needed drawn from the UPCI, SPORE Internal & External Advisory Board, and other SPOREs at UPCI, and/or other Head and Neck SPOREs will continue to provide rigorous and consistent peer review of the project proposals. Proposals will be solicited and reviewed on an annual basis. These activities of the DRP will continue to stimulate innovative research toward meeting the translational goals of the SPORE: reduction in the incidence, morbidity, and mortality from head and neck cancers.

Public Health Relevance

DRP This required program provides resources to recruit new investigators into the field of head and neck cancer translational research. The Head and Neck SPORE will identify and support innovative high-risk, high-reward pilot research in head and neck and cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097190-15
Application #
9736285
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
15
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15260
Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Pai, Sara I; Jack Lee, J; Carey, Thomas E et al. (2018) HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncol 77:92-97
Shayan, Gulidanna; Kansy, Benjamin A; Gibson, Sandra P et al. (2018) Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res 24:62-72
Lee, Yoon Se; Johnson, Daniel E; Grandis, Jennifer R (2018) An update: emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs :1-17
Johnson, Daniel E; O'Keefe, Rachel A; Grandis, Jennifer R (2018) Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15:234-248
Close, David A; Camarco, Daniel P; Shan, Feng et al. (2018) The Generation of Three-Dimensional Head and Neck Cancer Models for Drug Discovery in 384-Well Ultra-Low Attachment Microplates. Methods Mol Biol 1683:355-369
Yang, Xi; Xia, Rui; Yue, Cuihua et al. (2018) ATF4 Regulates CD4+ T Cell Immune Responses through Metabolic Reprogramming. Cell Rep 23:1754-1766
Njatcha, Christian; Farooqui, Mariya; Kornberg, Adam et al. (2018) STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer. Mol Cancer Ther 17:1917-1926
Johnston, Paul A; Sen, Malabika; Hua, Yun et al. (2018) High Content Imaging Assays for IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. Methods Mol Biol 1683:229-244

Showing the most recent 10 out of 310 publications